Absorption-enhancing treatments for antihypertensive activity of oligopeptides from tuna cooking juice: in vivo evaluation in spontaneously hypertensive rats

• Published in: Journal of food science 2006-01, Vol.71 (1), p.S13-S17
• Main Authors: Ko, W.C, Cheng, M.L, Hsu, K.C, Hwang, J.S
• Format: Article
• Language: English
• Subjects: absorption; absorption-enhancing treatment; angiotensin I; angiotensin I-converting enzyme (ACE); animal byproducts; animal disease models; antihypertensive effect; antihypertensive property; Bioavailability; Biological and medical sciences; cooking; dose response; emulsifying; enzyme inhibitors; Enzymes; Fish; fish products; Food industries; functional foods; Fundamental and applied biological sciences. Psychology; gum arabic; human diseases; hydrolysates; Hypertension; lipophilization; microencapsulation; oligopeptides; oral administration; peptidases; Peptides; peptidyl-dipeptidase A; phosphatidylcholines; rats; Rodents; systolic blood pressure; Thunnus; tuna; tuna cooking juice
• ISSN: 0022-1147; 1750-3841
• DOI: 10.1111/j.1365-2621.2006.tb12399.x

The aim of this study was to evaluate the absorption-enhancing effect for antihypertensive activity of an angiotensin I-converting enzyme (ACE) inhibitory oligopeptides in spontaneously hypertensive rats (SHR). The oligopeptides OA3, derived from tuna cooking juice, significantly reduced systolic blood pressure (SBP) in SHR at the doses of 0.5, 0.75, and 1.0 g/kg body weight; their efficacies were exhibited in a dose-dependent manner. Emulsification, microencapsulation, and lipophilization were applied to enhance the antihypertensive activity of OA3 at the dose of 0.5 g/kg body weight in SHR individually. Lipophilization revealed most effectively by 16 mm Hg in SBP in SHR 4 h after oral administration; the significant different effect lasted more than 6 h. Such efficacy is greater than that from no further treated OA3 with the dose of 1.0 g/kg body weight. Enhancing treatments by using 30% gum Arabic and 30% lecithin exhibited minor effects by 13 and 11 mm Hg, respectively. Results imply that these additional treatments could further enhance and extend the antihypertensive effect of OA3 oligopeptides. This suggests that absorption-enhancing treatments improve the bioavailability of oligopeptides to exhibit higher antihypertensive effect. Furthermore, these enhancing effects may be brought about by the changes in cell membrane permeation or the protection of oligopeptides.